Pacira BioSciences Studies Preliminary Second Quarter 2022 Income of $169.4 Million | Information

TAMPA, Fla., July 14, 2022 (GLOBE NEWSWIRE) — Pacira BioSciences, Inc. (Nasdaq: PCRX), the business chief in its dedication to non-opioid ache administration and regenerative well being options, at this time reported preliminary revenues of $169.4 million for the second quarter of 2022, in contrast with $135.6 million for the second quarter of 2021. The corporate’s revenues embrace web product gross sales of EXPAREL® (bupivacaine liposome injectable suspension), ZILRETTA® (triamcinolone acetonide extended-release injectable suspension), and the iovera° system. The corporate started recognizing gross sales of ZILRETTA in November 2021 after finishing its acquisition of Flexion Therapeutics, Inc.

“We proceed to execute our development technique and are happy to have posted document gross sales within the second quarter. In mid-June, EXPAREL gross sales developments strengthened regardless of ongoing pockets of persistent labor shortages and pandemic-related disruptions going through the elective surgical procedure market. This was augmented by ZILRETTA gross sales, which underscore the profitable integration of this synergistic product,” stated Dave Stack, chairman and chief government officer of Pacira BioSciences. “EXPAREL has continued to outpace the restoration of the elective surgical procedure market and we’re seeing increasing utilization throughout all goal markets and websites of care, with notably sturdy development inside outpatient websites of care. We proceed to drive training and consciousness across the worth of ZILRETTA and iovera° as each complementary and standalone non-opioid options for managing osteoarthritis ache and stay assured within the long-term development alternative for each merchandise.”

“On the scientific entrance, we stay on monitor with actions advancing based on plan. We have now accomplished enrollment within the first of two research evaluating EXPAREL as a decrease extremity nerve block and we anticipate to finish enrollment within the second research within the coming weeks. We’re additionally finalizing the design of our label enlargement research for ZILRETTA in shoulder osteoarthritis and kind 2 diabetes. As well as, we’re getting ready to fulfill with the U.S. Meals and Drug Administration (FDA) to debate the design of our Section 3 registration research for iovera° as a therapy for spasticity. With a complementary portfolio of progressive non-opioid choices, we consider we’re uniquely positioned to ship sturdy near- and long-term development,” continued Mr. Stack.

Second Quarter and June 2022 Preliminary Income Highlights

  • EXPAREL web product gross sales had been $137.0 million and $130.1 million for the second quarters of 2022 and 2021 and $47.3 million and $45.8 million for the months of June 2022 and 2021, respectively. EXPAREL common every day gross sales had been 105 % of the prior yr for the second quarter and 103 % of the prior yr for the month of June, respectively. The corporate stories common every day development charges for EXPAREL to account for variations within the variety of promoting days per reporting interval. For the second quarter, EXPAREL promoting days had been 64 in each 2022 and 2021. For the month of June, EXPAREL promoting days had been 22 in 2022 and 2021. Gross sales of bupivacaine liposome injectable suspension to a third-party licensee to be used in veterinary observe had been $1.0 million and $1.0 million within the second quarters of 2022 and 2021, respectively.
  • ZILRETTA web product gross sales had been $27.4 million for the second quarter of 2022 and $9.8 million for the month of June 2022.   ZILRETTA gross sales within the second quarter of 2021 occurred previous to the completion of the corporate’s acquisition of Flexion in November 2021.  
  • iovera° web product gross sales had been $3.2 million and $3.8 million for the second quarters of 2022 and 2021 and $1.1 million and $1.4 million for the months of June 2022 and 2021, respectively.
  • Second quarter 2022 royalty income was $0.8 million, in contrast with $0.6 million in 2021.

Since early 2020, the corporate’s revenues have been impacted by COVID-19 and pandemic-related challenges that included the numerous postponement or suspension within the scheduling of elective surgical procedures as a consequence of public well being steering and authorities directives. Whereas the diploma of impression has diminished in the course of the course of the pandemic because of the introduction of vaccines and the lessening of elective surgical procedure restrictions, sure pandemic-related operational challenges persist. It stays unclear how lengthy it’s going to take the elective surgical procedure market to normalize or if restrictions on elective procedures will recur as a consequence of future COVID-19 variants or in any other case.

The corporate shouldn’t be offering 2022 income or gross margin steering at the moment given the continued uncertainty round labor shortages, COVID-19, and the tempo of restoration for the elective surgical procedure market. To supply larger transparency, the corporate is reporting month-to-month intra-quarter unaudited web product gross sales for EXPAREL, ZILRETTA, and iovera° till it has gained sufficient visibility across the impacts of COVID-19. The corporate can be offering weekly EXPAREL utilization and elective surgical procedure information inside its investor presentation, which is accessible at  Pacira accomplished its acquisition of Flexion Therapeutics on November 19, 2021, which added ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) to its industrial providing.

The monetary info included on this press launch is preliminary, unaudited, and topic to adjustment. It doesn’t current all info vital for an understanding of the corporate’s monetary outcomes for the second quarter or full yr 2022.

About Pacira BioSciences

Pacira BioSciences, Inc. (Nasdaq: PCRX) is dedicated to offering a non-opioid choice to as many sufferers as potential to redefine the function of opioids as rescue remedy solely. The corporate can be creating progressive interventions to handle debilitating circumstances involving the sympathetic nervous system, reminiscent of cardiac electrical storm, power ache, and spasticity. Pacira has three commercial-stage non-opioid remedies: EXPAREL® (bupivacaine liposome injectable suspension), a long-acting, native analgesia presently authorised for postsurgical ache administration; ZILRETTA® (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular, injection indicated for the administration of osteoarthritis knee ache; and ioveraº®, a novel, handheld machine for delivering rapid, long-acting, drug-free ache management utilizing exact, managed doses of chilly temperature to a focused nerve. To study extra about Pacira, together with the company mission to scale back overreliance on opioids, go to


EXPAREL (bupivacaine liposome injectable suspension) is indicated in sufferers 6 years of age and older for single-dose infiltration to supply postsurgical native analgesia, and in adults as an interscalene brachial plexus nerve block to supply postsurgical regional analgesia. Security and efficacy haven’t been established in different nerve blocks. Since its launch, EXPAREL has been utilized in over 9 million sufferers. EXPAREL makes use of the corporate’s proprietary multivesicular liposomal drug supply expertise composed of a honeycomb of quite a few, non-concentric, inner aqueous chambers containing bupivacaine. After injection, bupivacaine is launched over time, because the lipid membranes are absorbed, prolonging the period of motion. EXPAREL is the primary and solely multivesicular liposome native anesthetic that may be utilized within the peri- or postsurgical setting. A single dose of EXPAREL supplies important reductions in cumulative ache scores with as much as a 78 % lower in opioid consumption; the scientific good thing about the opioid discount was not demonstrated. Further info is accessible at

Necessary Security Details about EXPAREL for Sufferers

EXPAREL shouldn’t be utilized in obstetrical paracervical block anesthesia. In research in adults the place EXPAREL was injected right into a wound, the commonest unwanted effects had been nausea, constipation, and vomiting. In research in adults the place EXPAREL was injected close to a nerve, the commonest unwanted effects had been nausea, fever, and constipation. Within the research the place EXPAREL was given to kids, the commonest unwanted effects had been nausea, vomiting, constipation, low blood stress, low variety of purple blood cells, muscle twitching, blurred imaginative and prescient, itching, and fast heartbeat. EXPAREL may cause a short lived lack of feeling and/or lack of muscle motion. How a lot and the way lengthy the lack of feeling and/or muscle motion relies on the place and the way a lot of EXPAREL was injected and will final for as much as 5 days. EXPAREL shouldn’t be really useful for use in sufferers youthful than 6 years outdated for injection into the wound, for sufferers youthful than 18 years outdated for injection close to a nerve, and/or in pregnant ladies. Inform your well being care supplier if you happen to or your youngster has liver illness, since this may occasionally have an effect on how the energetic ingredient (bupivacaine) in EXPAREL is eradicated from the physique. EXPAREL shouldn’t be injected into the backbone, joints, or veins. The energetic ingredient in EXPAREL can have an effect on the nervous system and the cardiovascular system; might trigger an allergic response; might trigger injury if injected into the joints; and might trigger a uncommon blood dysfunction.


On October 6, 2017, ZILRETTA (triamcinolone acetonide extended-release injectable suspension) was authorised by the U.S. Meals and Drug Administration as the primary and solely extended-release intra-articular remedy for sufferers confronting osteoarthritis (OA)- associated knee ache. ZILRETTA employs proprietary microsphere expertise combining triamcinolone acetonide—a generally administered, short-acting corticosteroid—with a poly lactic-co-glycolic acid (PLGA) matrix to supply prolonged ache reduction. The pivotal Section 3 trial on which the approval of ZILRETTA was primarily based confirmed that ZILRETTA considerably lowered OA knee ache for 12 weeks, with some individuals experiencing ache reduction by means of Week 16. Be taught extra at

Indication and Choose Necessary Security Data for ZILRETTA

Indication: ZILRETTA is indicated as an intra-articular injection for the administration of OA ache of the knee. Limitation of Use: The efficacy and security of repeat administration of ZILRETTA haven’t been demonstrated.

Contraindication: ZILRETTA is contraindicated in sufferers who’re hypersensitive to triamcinolone acetonide, corticosteroids or any elements of the product.

Warnings and Precautions:

  • Intra-articular Use Solely: ZILRETTA has not been evaluated and shouldn’t be administered by epidural, intrathecal, intravenous, intraocular, intramuscular, intradermal, or subcutaneous routes. ZILRETTA shouldn’t be thought of protected for epidural or intrathecal administration.
  • Severe Neurologic Antagonistic Reactions with Epidural and Intrathecal Administration: Severe neurologic occasions have been reported following epidural or intrathecal corticosteroid administration. Corticosteroids will not be authorised for this use.
  • Hypersensitivity reactions: Severe reactions have been reported with triamcinolone acetonide injection. Institute acceptable care if an anaphylactic response happens.
  • Joint an infection and injury: A marked enhance in joint ache, joint swelling, restricted movement, fever and malaise might counsel septic arthritis. If this happens, conduct acceptable analysis and if confirmed, institute acceptable antimicrobial therapy.

Antagonistic Reactions: Probably the most generally reported antagonistic reactions (incidence ≥1%) in scientific research included sinusitis, cough, and contusions.

Please see  for full Prescribing Data.

About iovera°®

The iovera° system is used to destroy tissue throughout surgical procedures by making use of freezing chilly. It can be used to supply lesions in peripheral nervous tissue by the appliance of chilly to the chosen web site for the blocking of ache. It is usually indicated for the reduction of ache and signs related to osteoarthritis of the knee for as much as 90 days. In a single research, nearly all of the sufferers affected by osteoarthritis of the knee skilled ache and system reduction past 150 days. The iovera° system’s “1×90” Sensible Tip configuration (indicating one needle which is 90 mm lengthy) also can facilitate goal nerve location by conducting electrical nerve stimulation from a separate nerve stimulator. The iovera° system shouldn’t be indicated for therapy of central nervous system tissue. Further info is accessible at

Necessary Security Data for iovera°®

The iovera° system is contraindicated to be used in sufferers with the next: Cryoglobulinemia; Paroxysmal chilly hemoglobinuria; chilly urticaria; Raynaud’s illness; open and/or contaminated wounds at or close to the therapy line. Potential issues: As with all surgical therapy that makes use of needle-based remedy, there may be potential for short-term site-specific reactions, together with however not restricted to: bruising (ecchymosis); swelling (edema); irritation and/or redness (erythema); ache and/or tenderness; altered sensation (localized dysesthesia). Usually, these reactions resolve with no doctor intervention. Sufferers might assist the therapeutic course of by making use of ice packs to the affected websites, and by taking over-the-counter analgesics.

Ahead-Trying Statements

Any statements on this press launch about Pacira’s future expectations, plans, developments, outlook, projections and prospects, and different statements containing the phrases “believes,” “anticipates,” “plans,” “estimates,” “expects,” “intends,” “might,” “will,” “would,” “might,” “can” and comparable expressions, represent forward-looking statements throughout the which means of the Personal Securities Litigation Reform Act of 1995. These forward-looking statements embrace, with out limitation, statements associated to the acquisition of Flexion Therapeutics, Inc. and the prices and advantages thereof, our development and future working outcomes and developments, our technique, plans, goals, expectations (monetary or in any other case) and intentions, future monetary outcomes and development potential, anticipated product portfolio, growth applications, strategic alliances, patent phrases and mental property and different statements that aren’t historic information. For this goal, any assertion that isn’t an announcement of historic truth needs to be thought of a forward-looking assertion. We can’t guarantee you that our estimates, assumptions and expectations will show to have been right. Precise outcomes might differ materially from these indicated by such forward-looking statements on account of numerous vital components, together with dangers referring to, amongst others: dangers related to acquisitions, reminiscent of the danger that the companies won’t be built-in efficiently, that such integration could also be harder, time-consuming or expensive than anticipated or that the anticipated advantages of the transaction won’t happen; the chance that if we don’t obtain the perceived advantages of the Flexion acquisition as quickly or to the extent anticipated by monetary analysts or buyers, the market worth of our shares might decline; the impression of the COVID-19 pandemic on elective surgical procedures, our manufacturing and provide chain, international and United States financial circumstances, and our enterprise, together with our revenues, monetary situation and outcomes of operations; the success of our gross sales and manufacturing efforts in help of the commercialization of EXPAREL, ZILRETTA and iovera° and the speed and diploma of market acceptance of EXPAREL, ZILRETTA and iovera°; the scale and development of the potential markets for EXPAREL, ZILRETTA and iovera° and our means to serve these markets; our plans to broaden using EXPAREL, ZILRETTA and iovera° to further indications and alternatives, and the timing and success of any associated scientific trials for EXPAREL, ZILRETTA and iovera°; the industrial success of EXPAREL, ZILRETTA and iovera°; the associated timing and success of United States Meals and Drug Administration supplemental New Drug Functions, and premarket notification 510(okay)s; the associated timing and success of European Medicines Company Advertising Authorization Functions; our plans to guage, develop and pursue further product candidates using our proprietary multivesicular liposome (pMVL) drug supply expertise; the approval of the commercialization of our merchandise in different jurisdictions; scientific trials in help of an present or potential pMVL-based product; our commercialization and advertising and marketing capabilities, our means to efficiently assemble a further EXPAREL manufacturing suite in San Diego, California; our means to efficiently full a ZILRETTA capability enlargement mission in Swindon, England; the result of any litigation; the power to efficiently combine Flexion or any future acquisitions into our present enterprise; the recoverability of our deferred tax belongings; and assumptions related to contingent consideration funds; and components mentioned within the “Danger Elements” of our most up-to-date Annual Report on Kind 10-Okay and in different filings that we periodically make with the Securities and Alternate Fee. As well as, the forward-looking statements included on this press launch characterize our views as of the date of this press launch. Necessary components might trigger precise outcomes to vary materially from these indicated or implied by forward-looking statements, and as such we anticipate that subsequent occasions and developments will trigger our views to vary. Nonetheless, whereas we might elect to replace these forward-looking statements in some unspecified time in the future sooner or later, we particularly disclaim any obligation to take action, besides as required by legislation. These forward-looking statements shouldn’t be relied upon as representing our views as of any date subsequent to the date of this press launch.

Investor Contact: Susan Mesco, (973) 451-4030 Media Contact: Coyne Public Relations Kristin Capone, (973) 588-2108


Leave a Reply

Your email address will not be published. Required fields are marked *